Double-Blind Extension of the Study 27025 (REFLEX) to Obtain Long-Term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION)

Authors Merck KGaA, Darmstadt, Germany -More
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2008
Links ClinicalTrials.gov
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum \[FBS\]-free/human serum albumin \[HSA\]-free formulation of interferon \[IFN\]-beta-1a (RNF).
Epistemonikos ID: 73d20379e820b6de749f236a913f1827b8dc1d8c
First added on: Mar 31, 2022